Angiotensin II Type 2 Receptor Antibody [F9C2]

N° de catalogue F2225

Imprimer

Description biologique

Spécificité

Angiotensin II Type 2 Receptor Antibody [F9C2] reconnaît les niveaux endogènes de la protéine totale du récepteur de type 2 de l'angiotensine II.

Contexte

Le Angiotensin II Type 2 Receptor (AT2R), membre de la famille des GPCR & G Protein, est lié à des protéines stimulantes (Gαs) ou inhibitrices (Gαi/o) et à des voies indépendantes des protéines G qui impliquent des protéines de liaison à l'AT2R. Son activation déclenche des enzymes telles que la SHP-1 (phosphatase 1 contenant un domaine SH2), la MKP-1 (mitogen-activated protein kinase phosphatase 1) et la PP2A (protéine phosphatase 2A), qui jouent des rôles significatifs dans les voies de signalisation. L'AT2R est essentiel pour la protection cardiovasculaire et rénale en réduisant l'inflammation, en améliorant la fonction ventriculaire, en diminuant le tissu cicatriciel et en prévenant le remodelage cardiaque néfaste par la modulation de l'apoptose et les voies de survie cellulaire. L'absence d'AT2R entraîne une aggravation de l'insuffisance cardiaque, tandis qu'une surexpression modérée améliore la fonction cardiaque après une lésion. Son activation est également liée à une fibrose réduite, à une amélioration du débit de filtration glomérulaire (DFG) et à une inflammation réduite, particulièrement bénéfique dans les affections rénales comme la néphropathie diabétique. Il présente des effets anti-inflammatoires en abaissant les cytokines telles que le TNF-α et l'IL-6 et en augmentant l'IL-10, ce qui contribue à la modulation des cellules immunitaires pour la santé cardiaque et rénale. Son interaction avec le MasR est prometteuse pour le traitement du SARS-CoV-2 en contrecarrant potentiellement la régulation négative de l'ACE2 due au virus, restaurant ainsi la voie de signalisation avantageuse Ang (1–7)/MasR.

Informations dutilisation

Application WB, IP Dilution
WB IP
1:1000-1:10000 1:20
Réactivité Human, Mouse, Rat
Source Rabbit Monoclonal Antibody MW 41 kDa
Tampon de stockage PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN₃
Stockage
(À partir de la date de réception)
–20°C (avoid freeze-thaw cycles), 2 years
WB
Experimental Protocol:
 
Sample preparation
1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
2. Adherent cell: Aspirate the culture medium and transfer the cells into an EP tube. Wash the cells with ice-cold PBS twice. Add an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail), sonicate to lyse the cells, and incubate on ice for 30 minutes.
3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice.Add an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail), sonicate to lyse the cells, and incubate on ice for 30 minutes.
4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
5. Remove a small volume of lysate to determine the protein concentration;
6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
 
Electrophoretic separation
1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
 
Transfer membrane
1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
Recommended conditions for wet transfer: 200 mA, 120 min.
( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
 
Block
1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
2. Incubate the film in the blocking solution for 1 hour at room temperature;
3. Wash the film with TBST for 3 times, 5 minutes each time.
 
Antibody incubation
1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
2. Wash the film with TBST 3 times, 5 minutes each time;
3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
 
Antibody staining
1059. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.

Références

  • https://pubmed.ncbi.nlm.nih.gov/33840201/

Données dapplication

WB

Validé par Selleck

  • F2225-wb
    Lane 1: HepG2
    Lane 2: Human heart
    Lane 3: Mouse heart
    Lane 4: Rat heart